|
US3117142A
(en)
|
1961-03-01 |
1964-01-07 |
Roussel Uclaf |
Novel preparation of estradiol and estrone
|
|
US3169134A
(en)
|
1963-03-21 |
1965-02-09 |
Searle & Co |
2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
|
|
BE754111A
(fr)
|
1969-07-29 |
1971-01-29 |
Upjohn Co |
Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
|
|
US3943124A
(en)
|
1970-12-17 |
1976-03-09 |
Gordon Hanley Phillipps |
Chemical compounds
|
|
US3983111A
(en)
|
1972-05-05 |
1976-09-28 |
Glaxo Laboratories Limited |
Steroidal anaesthetics of the pregnane and 19-norpregnane series
|
|
GB1430942A
(en)
|
1972-05-05 |
1976-04-07 |
Glaxo Lab Ltd |
21-substituted 3alpha-hydroxy pregnanes
|
|
US3865939A
(en)
|
1973-02-23 |
1975-02-11 |
Procter & Gamble |
Edible oils having hypocholesterolemic properties
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
|
GB1570394A
(en)
|
1976-01-06 |
1980-07-02 |
Glaxo Lab Ltd |
11-acyloxy-3-hydroxy steroids
|
|
US4192871A
(en)
|
1976-01-06 |
1980-03-11 |
Glaxo Laboratories Limited |
Chemical compounds
|
|
GB1581234A
(en)
|
1976-04-05 |
1980-12-10 |
Glaxo Operations Ltd |
11a - amino - 3a - hydroxysteroids
|
|
SE8600632D0
(sv)
|
1986-02-13 |
1986-02-13 |
Kabivitrum Ab |
Novel pharmaceutical composition
|
|
US5120723A
(en)
|
1987-08-25 |
1992-06-09 |
University Of Southern California |
Method, compositions, and compounds for modulating brain excitability
|
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
|
US5319115A
(en)
|
1987-08-25 |
1994-06-07 |
Cocensys Inc. |
Method for making 3α-hydroxy, 3β-substituted-pregnanes
|
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
JPH06510999A
(ja)
|
1991-09-13 |
1994-12-08 |
コセンシス・インコーポレイテッド |
ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
|
|
EP0701444B1
(en)
|
1993-05-24 |
2010-04-07 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
|
EP0656365B1
(en)
|
1993-12-02 |
1997-04-09 |
Akzo Nobel N.V. |
Substituted 2beta-morpholinoandrostane derivatives
|
|
US5939545A
(en)
|
1994-02-14 |
1999-08-17 |
Cocensys, Inc. |
Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
|
|
PT752860E
(pt)
|
1994-02-14 |
2000-12-29 |
Euro Celtique Sa |
Androstanos e pregnanos para modulacao alosterica do receptor de gaba
|
|
KR20040068613A
(ko)
|
1994-03-25 |
2004-07-31 |
이소테크니카 인코포레이티드 |
중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
|
|
AU3125695A
(en)
|
1994-07-21 |
1996-02-22 |
Pharmacia & Upjohn Company |
Neurologically active aminosteroids
|
|
CN1171114A
(zh)
|
1994-11-23 |
1998-01-21 |
科斯赛斯公司 |
用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
|
|
US6780853B1
(en)
|
1995-06-06 |
2004-08-24 |
Euro-Celtique S.A. |
Neuroactive steroids of the androstane and pregnane series
|
|
CA2223996A1
(en)
|
1995-06-06 |
1996-12-19 |
Cocensys, Inc. |
Neuroactive steroids of the androstane and pregnane series
|
|
WO1997003677A1
(en)
|
1995-07-24 |
1997-02-06 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
|
WO1998005337A1
(en)
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
|
US7630757B2
(en)
|
1997-01-06 |
2009-12-08 |
Flint Hills Scientific Llc |
System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
|
|
US5874418A
(en)
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
US6046177A
(en)
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
US6316613B1
(en)
|
1997-07-25 |
2001-11-13 |
Beckman Coulter, Inc. |
Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
|
|
US6245757B1
(en)
|
1997-10-03 |
2001-06-12 |
Research Corporation Technologies, Inc. |
Use of progestins to treat ischemic event
|
|
ATE307592T1
(de)
|
1998-03-11 |
2005-11-15 |
Torbjoern Backstroem |
Epiallopregnanolon zur behandlung von krankheiten des cns
|
|
US20020198174A1
(en)
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
US6376531B1
(en)
|
1998-11-13 |
2002-04-23 |
Rupert Charles Bell |
Method of treatment using deuterium compounds
|
|
US20030236236A1
(en)
|
1999-06-30 |
2003-12-25 |
Feng-Jing Chen |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
|
EP1218003A4
(en)
*
|
1999-09-13 |
2004-02-11 |
David M Swope |
COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
|
|
PT1104760E
(pt)
|
1999-12-03 |
2003-06-30 |
Pfizer Prod Inc |
Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
|
|
US6613308B2
(en)
|
2000-09-19 |
2003-09-02 |
Advanced Inhalation Research, Inc. |
Pulmonary delivery in treating disorders of the central nervous system
|
|
US20020072509A1
(en)
|
2000-10-11 |
2002-06-13 |
Stein Donald Gerald |
Methods for the treatment of a traumatic central nervous system injury
|
|
EP1216713A1
(en)
|
2000-12-20 |
2002-06-26 |
Schering Aktiengesellschaft |
Compositions of estrogen-cyclodextrin complexes
|
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
|
WO2002064804A2
(en)
|
2001-02-13 |
2002-08-22 |
University Of Florida |
A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
|
|
US20030055026A1
(en)
|
2001-04-17 |
2003-03-20 |
Dey L.P. |
Formoterol/steroid bronchodilating compositions and methods of use thereof
|
|
US20030032638A1
(en)
|
2001-05-24 |
2003-02-13 |
Kim John J. |
Delivery of benzodiazepines through an inhalation route
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
WO2002094218A2
(en)
|
2001-05-24 |
2002-11-28 |
Alexza Molecular Delivery Corporation |
Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
|
|
JP2003063965A
(ja)
|
2001-06-13 |
2003-03-05 |
Otsuka Pharmaceut Factory Inc |
注射用シロスタゾール水性製剤
|
|
SE0104423D0
(sv)
*
|
2001-12-27 |
2001-12-27 |
Umecrine Ab |
Pregnane steroids and their use in the treatment of CNS disorders
|
|
AU2003252827B2
(en)
|
2002-01-14 |
2008-01-10 |
Ansell Healthcare Products Llc |
Magnetically detectable latex articles
|
|
US20040138187A1
(en)
|
2002-08-28 |
2004-07-15 |
Reading Christopher L. |
Therapeutic treatment methods
|
|
US20040132826A1
(en)
*
|
2002-10-25 |
2004-07-08 |
Collegium Pharmaceutical, Inc. |
Modified release compositions of milnacipran
|
|
US9339508B2
(en)
|
2003-01-17 |
2016-05-17 |
Mapreg |
Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
|
|
US7781421B2
(en)
|
2003-05-29 |
2010-08-24 |
Washington University |
Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods
|
|
US7816074B2
(en)
|
2003-07-31 |
2010-10-19 |
The Research Foundation Of State University Of New York |
α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
|
|
GB0321607D0
(en)
|
2003-09-15 |
2003-10-15 |
Vectura Ltd |
Manufacture of pharmaceutical compositions
|
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
DE602005026225D1
(de)
|
2004-03-12 |
2011-03-24 |
Cipla Ltd |
Sterilisationsprozess für Steroide
|
|
WO2005105822A2
(en)
|
2004-04-23 |
2005-11-10 |
Euro-Celtique S.A. |
3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
|
|
EP1591455A1
(en)
*
|
2004-04-29 |
2005-11-02 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Essential tremor diagnostic and treatment
|
|
ITMI20041763A1
(it)
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
US8604011B2
(en)
*
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
|
EP1807118B8
(en)
|
2004-09-29 |
2014-04-23 |
Harbor Therapeutics, Inc. |
Steroid analogs and characterization and treatment methods
|
|
MX2007009915A
(es)
|
2005-02-15 |
2007-11-06 |
Elan Pharma Int Ltd |
Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
|
|
EP2030622B1
(en)
|
2005-03-24 |
2011-02-23 |
Emory University |
Indication of dosage of progesterone in the treatment of a traumatic brain injury
|
|
EP1868593A2
(en)
|
2005-04-07 |
2007-12-26 |
Hythiam, Inc. |
Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
CA2631233C
(en)
|
2005-11-28 |
2011-11-08 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
|
US20070287931A1
(en)
|
2006-02-14 |
2007-12-13 |
Dilorenzo Daniel J |
Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
|
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20090239942A1
(en)
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
US20090203658A1
(en)
|
2007-01-08 |
2009-08-13 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US20090074677A1
(en)
*
|
2007-01-08 |
2009-03-19 |
Duke University |
Neuroactive steroid compositions and methods of use therefor
|
|
US7813811B2
(en)
|
2007-02-08 |
2010-10-12 |
Neuropace, Inc. |
Refillable reservoir lead systems
|
|
CA2682598C
(en)
|
2007-04-11 |
2016-06-07 |
Biomarin Pharmaceutical Inc. |
Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
|
|
US8530463B2
(en)
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
|
JP2010530371A
(ja)
|
2007-06-11 |
2010-09-09 |
ユニバーシティ オブ サザン カリフォルニア |
神経学的機能を増強するための作用物質、組成物および方法
|
|
ES2589139T3
(es)
|
2007-06-15 |
2016-11-10 |
Research Triangle Institute |
Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
|
|
GB0711948D0
(en)
|
2007-06-20 |
2007-08-01 |
Bionature E A Ltd |
Neurosteriod compounds
|
|
WO2009000038A1
(en)
|
2007-06-28 |
2008-12-31 |
Cnsbio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
WO2009082039A1
(en)
|
2007-12-26 |
2009-07-02 |
Eisai R & D Management Co., Ltd. |
Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
|
|
CA2711160A1
(en)
|
2008-01-03 |
2009-07-16 |
Biomarin Pharmaceutical Inc. |
Pterin analog for treating bh4 responsive condition
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
|
CZ2008434A3
(cs)
|
2008-07-10 |
2009-12-09 |
Ústav organické chemie a biochemie Akademie ved CR, v. v. i. |
Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
|
|
CN106243100B
(zh)
|
2008-10-10 |
2019-04-09 |
Vm生物医药公司 |
治疗酒精使用障碍，疼痛和其他疾病的药物组合与方法
|
|
EP2376073A2
(en)
|
2008-11-30 |
2011-10-19 |
Oron Zachar |
Dermal application of vasoconstrictors
|
|
US20110306579A1
(en)
|
2009-01-30 |
2011-12-15 |
Emory University |
Methods of neuroprotection using neuroprotective steroids and a vitamin d
|
|
US20120142645A1
(en)
*
|
2009-03-17 |
2012-06-07 |
Marx Christine E |
Neuroactive steroid compositions and methods of use for lowering cholesterol
|
|
US20110152840A1
(en)
|
2009-12-23 |
2011-06-23 |
Drugtech Corporation |
Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
|
|
US8697678B2
(en)
|
2010-01-21 |
2014-04-15 |
Drawbridge Pharmaceuticals Pty Ltd |
Anaesthetic formulation
|
|
CN103313744B
(zh)
|
2010-11-03 |
2015-06-10 |
赛诺菲-安万特德国有限公司 |
容纳药物的针插管
|
|
WO2012075286A2
(en)
|
2010-12-01 |
2012-06-07 |
The Regents Of The University Of California |
Intrapulmonary benzodiazepine for the treatment and prevention of seizures
|
|
CZ201181A3
(cs)
|
2011-02-15 |
2012-09-12 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
|
|
WO2012116290A2
(en)
|
2011-02-25 |
2012-08-30 |
Washington University |
Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
FR2973031B1
(fr)
|
2011-03-23 |
2013-11-29 |
Univ Strasbourg |
Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
|
|
US9084797B2
(en)
|
2011-05-23 |
2015-07-21 |
Besins Healthcare Luxembourg Sarl |
Progesterone treatment for improving sleep quality
|
|
WO2013002584A2
(ko)
|
2011-06-28 |
2013-01-03 |
주식회사 비보존 |
다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
|
|
EP2736919A4
(en)
|
2011-07-29 |
2015-01-14 |
Univ California |
NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
|
CN107936076B
(zh)
|
2011-09-08 |
2021-10-15 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
CN113234114A
(zh)
|
2011-10-14 |
2021-08-10 |
萨奇治疗股份有限公司 |
3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
|
|
US20140322198A1
(en)
|
2011-11-29 |
2014-10-30 |
Amino Up Chemical Co., Ltd. |
Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
|
|
WO2013112605A2
(en)
|
2012-01-23 |
2013-08-01 |
Sage Therapeutics, Inc. |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
WO2013188792A2
(en)
|
2012-06-15 |
2013-12-19 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2014028398A2
(en)
|
2012-08-13 |
2014-02-20 |
The Regents Of The University Of California |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
|
|
HUE056838T2
(hu)
*
|
2012-08-21 |
2022-04-28 |
Sage Therapeutics Inc |
Allopregnanolon makacs epileptikus állapot kezelésére
|
|
WO2014058736A1
(en)
|
2012-10-08 |
2014-04-17 |
Washington University |
Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
|
|
EP2916846B1
(en)
|
2012-11-09 |
2025-09-17 |
Drawbridge Pharmaceuticals Pty Ltd |
Neuroactive steroids and their use to facilitate neuroprotection
|
|
WO2014085668A1
(en)
|
2012-11-30 |
2014-06-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
PT2935307T
(pt)
|
2012-12-18 |
2018-07-31 |
Univ Washington |
Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
|
|
WO2014108808A2
(en)
|
2013-01-09 |
2014-07-17 |
Henry James Lorne |
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
|
|
US20160068563A1
(en)
|
2013-04-17 |
2016-03-10 |
Boyd L. Harrison |
19-nor neuroactive steroids and methods of use thereof
|
|
TR201901745T4
(tr)
|
2013-04-17 |
2019-03-21 |
Sage Therapeutics Inc |
19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
|
|
SI2986624T1
(sl)
|
2013-04-17 |
2020-10-30 |
Sage Therapeutics, Inc. |
19-nor nevroaktivni steroidi za metode zdravljenja
|
|
US9725481B2
(en)
|
2013-04-17 |
2017-08-08 |
Sage Therapeutics, Inc. |
19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
|
|
PL3021852T3
(pl)
|
2013-07-19 |
2021-07-05 |
Sage Therapeutics, Inc. |
Neuroaktywne steroidy, kompozycje i ich zastosowania
|
|
PT3035940T
(pt)
|
2013-08-23 |
2019-01-28 |
Sage Therapeutics Inc |
Esteroides neuroativos, composições e seus usos
|
|
SMT202000406T1
(it)
|
2014-05-29 |
2020-09-10 |
Sage Therapeutics Inc |
Steroidi neuroattivi, composizioni e relativi usi
|
|
US10246482B2
(en)
|
2014-06-18 |
2019-04-02 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
KR20230170816A
(ko)
|
2014-10-16 |
2023-12-19 |
세이지 테라퓨틱스, 인크. |
Cns 장애의 치료를 위한 조성물 및 방법
|
|
PT3206493T
(pt)
|
2014-10-16 |
2020-08-03 |
Sage Therapeutics Inc |
Composições e métodos para tratamento de transtornos do snc
|
|
JP6893173B2
(ja)
|
2014-11-27 |
2021-06-23 |
セージ セラピューティクス， インコーポレイテッド |
Ｃｎｓ障害を処置するための組成物および方法
|
|
HUE054092T2
(hu)
|
2015-01-26 |
2021-08-30 |
Sage Therapeutics Inc |
Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
|
|
CA2973140C
(en)
|
2015-02-06 |
2025-09-16 |
Marinus Pharmaceuticals, Inc. |
Intravenous Ganaxolone Formulations and Their Use in the Treatment of Status Epilepticus and Other Epileptic Disorders
|
|
US10329320B2
(en)
|
2015-02-20 |
2019-06-25 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
|
WO2016164763A1
(en)
|
2015-04-10 |
2016-10-13 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
MA45276A
(fr)
|
2015-06-18 |
2018-04-25 |
Sage Therapeutics Inc |
Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
|
|
GB2541015A
(en)
|
2015-08-06 |
2017-02-08 |
Ge Oil & Gas Uk Ltd |
Subsea flying lead
|
|
CN108697712A
(zh)
|
2015-10-14 |
2018-10-23 |
加利福尼亚大学董事会 |
增强β细胞复制和/或存活
|
|
WO2017087864A1
(en)
|
2015-11-20 |
2017-05-26 |
Sage Therapeutics, Inc. |
Compounds and methods of their use
|
|
RU2766155C2
(ru)
|
2016-03-08 |
2022-02-08 |
Сейдж Терапьютикс, Инк. |
Нейроактивные стероиды, их композиции и применения
|
|
NZ790226A
(en)
|
2016-07-11 |
2025-08-29 |
Sage Therapeutics Inc |
C17, C20, and C21 substituted neuroactive steroids and their methods of use
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
JP2019524816A
(ja)
|
2016-08-11 |
2019-09-05 |
オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
てんかん性障害の処置のための方法および組成物
|
|
US20180050107A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Neurosteroid compositions and methods of use thereof
|
|
US20180050005A1
(en)
|
2016-08-16 |
2018-02-22 |
Janssen Pharmaceutica Nv |
Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
|
|
NZ791594A
(en)
|
2016-08-23 |
2025-08-29 |
Sage Therapeutics Inc |
A crystalline 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroid
|
|
KR102630701B1
(ko)
|
2016-09-07 |
2024-01-29 |
글리아, 엘엘씨 |
두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
WO2018169798A1
(en)
|
2017-03-11 |
2018-09-20 |
The Regents Of The University Of California |
Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
|
|
RU2019136361A
(ru)
|
2017-04-18 |
2021-05-13 |
Маринус Фармасьютикалс, Инк |
Инъекционные составы нейростеорида с замедленным высвобождением
|
|
US20180338959A1
(en)
|
2017-05-24 |
2018-11-29 |
Ovid Therapeutics Inc. |
Treatment of depressive disorders
|
|
US11752115B2
(en)
|
2017-06-21 |
2023-09-12 |
The Board Of Trustees Of The University Of Illinois |
PPAR-alpha agonist treatment of neuropsychiatric disorders
|
|
JP7557185B2
(ja)
|
2017-06-23 |
2024-09-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
免疫応答を調節するｇａｂａの能力の強化
|
|
WO2018237282A1
(en)
|
2017-06-23 |
2018-12-27 |
The Board Of Trustees Of The University Of Illinois |
Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
|
|
MX2020002652A
(es)
|
2017-09-07 |
2020-09-25 |
Sage Therapeutics Inc |
Esteroides neuroactivos y su método de uso.
|
|
US20200276209A1
(en)
|
2017-09-11 |
2020-09-03 |
Sage Therapeutics, Inc. |
Methods of treating epilepsy or status epilepticus
|
|
TW201919642A
(zh)
|
2017-09-14 |
2019-06-01 |
美商賽吉醫療公司 |
19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
|
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
|
EP3720867A1
(en)
|
2017-12-08 |
2020-10-14 |
Sage Therapeutics, Inc. |
Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
|
|
CN111770929B
(zh)
|
2017-12-22 |
2023-12-26 |
萨奇治疗股份有限公司 |
治疗cns疾病的组合物和方法
|
|
MX2020006608A
(es)
|
2017-12-22 |
2020-11-06 |
Sage Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
|
|
US11718642B2
(en)
|
2018-01-12 |
2023-08-08 |
Sage Therapeutics, Inc. |
Compositions and methods for treating CNS disorders
|
|
CN112823164A
(zh)
|
2018-05-04 |
2021-05-18 |
阿克罗斯制药公司 |
神经甾体衍生物和其用途
|
|
EP3806863A1
(en)
|
2018-06-12 |
2021-04-21 |
Sage Therapeutics, Inc. |
A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
|
|
WO2020077255A1
(en)
|
2018-10-12 |
2020-04-16 |
Sage Therapeutics, Inc. |
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
|
|
US20210363175A1
(en)
|
2018-10-19 |
2021-11-25 |
Sage Therapeutics, Inc. |
9(11)-unsaturated neuroactive steroids and their methods of use
|
|
US11311529B2
(en)
|
2018-11-08 |
2022-04-26 |
Varsona Therapeutics, Inc. |
Topical formulations of 5-α-reductase inhibitors and uses thereof
|
|
JP2022514194A
(ja)
|
2018-11-21 |
2022-02-10 |
セルテゴ セラピューティクス インコーポレイテッド |
自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
|
|
CA3120872A1
(en)
|
2018-12-05 |
2020-06-11 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
|
WO2020118437A1
(en)
|
2018-12-14 |
2020-06-18 |
Acerus Biopharma Inc. |
Active ester derivatives of testosterone, compositions and uses thereof
|
|
TWI892697B
(zh)
|
2018-12-21 |
2025-08-01 |
美商賽吉醫療公司 |
神經活性類固醇及其組合物
|
|
TW202523658A
(zh)
|
2019-05-24 |
2025-06-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
|
CN114206900A
(zh)
|
2019-05-31 |
2022-03-18 |
萨奇治疗股份有限公司 |
神经活性类固醇及其组合物
|
|
TWI896547B
(zh)
|
2019-06-27 |
2025-09-11 |
美商賽吉醫療公司 |
用於治療cns病症之組合物及方法
|
|
US20230257415A1
(en)
|
2019-06-27 |
2023-08-17 |
Sage Therapeutics, Inc. |
Compounds for treating cns disorders
|
|
CA3144701A1
(en)
|
2019-06-27 |
2020-12-30 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
|
JP2023504517A
(ja)
|
2019-12-05 |
2023-02-03 |
セージ セラピューティクス， インコーポレイテッド |
１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法
|
|
WO2021188778A2
(en)
|
2020-03-18 |
2021-09-23 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
|
JP2023519241A
(ja)
|
2020-03-25 |
2023-05-10 |
セージ セラピューティクス， インコーポレイテッド |
呼吸器状態の処置のための薬剤の使用
|
|
IL299176A
(en)
|
2020-06-24 |
2023-02-01 |
Sage Therapeutics Inc |
Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds
|
|
JP2023537240A
(ja)
|
2020-07-20 |
2023-08-31 |
セージ セラピューティクス， インコーポレイテッド |
１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドの製剤及びその使用方法
|
|
KR20230124916A
(ko)
|
2020-11-25 |
2023-08-28 |
세이지 테라퓨틱스, 인크. |
Cns 장애를 치료하기 위한 조성물 및 방법
|
|
US20240122945A1
(en)
|
2021-01-28 |
2024-04-18 |
Sage Therapeutics, Inc. |
Use of neuroactive steroids for treatment of sexual dysfunction
|
|
WO2022177718A1
(en)
|
2021-02-18 |
2022-08-25 |
Sage Therapeutics, Inc. |
Use of neuroactive steroid for treatment of sexual dysfunction
|
|
KR20230158033A
(ko)
|
2021-03-17 |
2023-11-17 |
세이지 테라퓨틱스, 인크. |
주요 우울 장애의 치료를 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
|
|
AU2022258203A1
(en)
|
2021-04-12 |
2023-10-26 |
Sage Therapeutics, Inc. |
Treatment of essential tremor
|
|
CN117580580A
(zh)
|
2021-04-29 |
2024-02-20 |
萨奇治疗股份有限公司 |
用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇
|
|
KR20240006026A
(ko)
|
2021-04-29 |
2024-01-12 |
세이지 테라퓨틱스, 인크. |
주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
|